IMPORTANCE Immune checkpoint blockade (ICB) has improved the survival of patients with advanced melanoma. Durable responses are observed for 40% to 60% of patients, depending on treatment regimens. However, there is still large variability in the response to treatment with ICB, and patients experience a range of immune-related adverse events of differing severity. Nutrition, through its association with the immune system and gut microbiome, isa poorly explored but appealing target with potential to improve the efficacy and tolerability of ICB.OBJECTIVE To investigate the association between habitual diet and response to treatment with ICB. DESIGN, SETTING, AND PARTICIPANTS This multicenter cohort study (the PRIMM study) was conducted in cancer centers in the Netherlands and UK and included 91 ICB-naive patients with advanced melanoma who were receiving ICB between 2018 and 2021.EXPOSURES Patients were treated with anti-programmed cell death 1 and anti-cytotoxic T lymphocyte-associated antigen 4 monotherapy or combination therapy. Dietary intake was assessed through food frequency questionnaires before treatment.MAIN OUTCOMES AND MEASURES Clinical end points were defined as overall response rate (ORR), progression-free survival at 12 months (PFS-12), and immune-related adverse events that were grade 2 or higher.RESULTS There were a total of 44 Dutch participants (mean [SD] age, 59.43 [12.74] years; 22 women [50%]) and 47 British participants (mean [SD] age, 66.21 [16.63] years; 15 women [32%]). Dietary and clinical data were prospectively collected from 91 patients receiving ICB between 2018 and 2021 for advanced melanoma in the UK and the Netherlands. Logistic generalized additive models revealed positive linear associations between a Mediterranean dietary pattern that was high in whole grains, fish, nuts, fruit, and vegetables and the probability of ORR and PFS-12 (probability of 0.77 for ORR; P = .02; false discovery rate, 0.032; effective degrees of freedom, 0.83; probability of 0.74 for PFS-12; P = .01; false discovery rate, 0.021; effective degrees of freedom, 1.54).CONCLUSIONS AND RELEVANCE This cohort study found a positive association between a Mediterranean diet, a widely recommended model of healthy eating, and response to treatment with ICB. Large prospective studies from different geographies are needed to confirm the findings and further elucidate the role of diet in the context of ICB.

Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma / Bolte, Laura A; Lee, Karla A; Björk, Johannes R; Leeming, Emily R; Campmans-Kuijpers, Marjo J E; de Haan, Jacco J; Vila, Arnau Vich; Maltez-Thomas, Andrew; Segata, Nicola; Board, Ruth; Harries, Mark; Lorigan, Paul; de Vries, Elisabeth G E; Nathan, Paul; Fehrmann, Rudolf; Bataille, Véronique; Spector, Tim D; Hospers, Geke A P; Weersma, Rinse K. - In: JAMA ONCOLOGY. - ISSN 2374-2437. - 9:5(2023), pp. 705-709. [10.1001/jamaoncol.2022.7753]

Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma

Maltez-Thomas, Andrew;Segata, Nicola;
2023-01-01

Abstract

IMPORTANCE Immune checkpoint blockade (ICB) has improved the survival of patients with advanced melanoma. Durable responses are observed for 40% to 60% of patients, depending on treatment regimens. However, there is still large variability in the response to treatment with ICB, and patients experience a range of immune-related adverse events of differing severity. Nutrition, through its association with the immune system and gut microbiome, isa poorly explored but appealing target with potential to improve the efficacy and tolerability of ICB.OBJECTIVE To investigate the association between habitual diet and response to treatment with ICB. DESIGN, SETTING, AND PARTICIPANTS This multicenter cohort study (the PRIMM study) was conducted in cancer centers in the Netherlands and UK and included 91 ICB-naive patients with advanced melanoma who were receiving ICB between 2018 and 2021.EXPOSURES Patients were treated with anti-programmed cell death 1 and anti-cytotoxic T lymphocyte-associated antigen 4 monotherapy or combination therapy. Dietary intake was assessed through food frequency questionnaires before treatment.MAIN OUTCOMES AND MEASURES Clinical end points were defined as overall response rate (ORR), progression-free survival at 12 months (PFS-12), and immune-related adverse events that were grade 2 or higher.RESULTS There were a total of 44 Dutch participants (mean [SD] age, 59.43 [12.74] years; 22 women [50%]) and 47 British participants (mean [SD] age, 66.21 [16.63] years; 15 women [32%]). Dietary and clinical data were prospectively collected from 91 patients receiving ICB between 2018 and 2021 for advanced melanoma in the UK and the Netherlands. Logistic generalized additive models revealed positive linear associations between a Mediterranean dietary pattern that was high in whole grains, fish, nuts, fruit, and vegetables and the probability of ORR and PFS-12 (probability of 0.77 for ORR; P = .02; false discovery rate, 0.032; effective degrees of freedom, 0.83; probability of 0.74 for PFS-12; P = .01; false discovery rate, 0.021; effective degrees of freedom, 1.54).CONCLUSIONS AND RELEVANCE This cohort study found a positive association between a Mediterranean diet, a widely recommended model of healthy eating, and response to treatment with ICB. Large prospective studies from different geographies are needed to confirm the findings and further elucidate the role of diet in the context of ICB.
2023
5
Bolte, Laura A; Lee, Karla A; Björk, Johannes R; Leeming, Emily R; Campmans-Kuijpers, Marjo J E; de Haan, Jacco J; Vila, Arnau Vich; Maltez-Thomas, Andrew; Segata, Nicola; Board, Ruth; Harries, Mark; Lorigan, Paul; de Vries, Elisabeth G E; Nathan, Paul; Fehrmann, Rudolf; Bataille, Véronique; Spector, Tim D; Hospers, Geke A P; Weersma, Rinse K
Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma / Bolte, Laura A; Lee, Karla A; Björk, Johannes R; Leeming, Emily R; Campmans-Kuijpers, Marjo J E; de Haan, Jacco J; Vila, Arnau Vich; Maltez-Thomas, Andrew; Segata, Nicola; Board, Ruth; Harries, Mark; Lorigan, Paul; de Vries, Elisabeth G E; Nathan, Paul; Fehrmann, Rudolf; Bataille, Véronique; Spector, Tim D; Hospers, Geke A P; Weersma, Rinse K. - In: JAMA ONCOLOGY. - ISSN 2374-2437. - 9:5(2023), pp. 705-709. [10.1001/jamaoncol.2022.7753]
File in questo prodotto:
File Dimensione Formato  
ONC22-1653_Merged_PDF.pdf

accesso aperto

Tipologia: Post-print referato (Refereed author’s manuscript)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 338.43 kB
Formato Adobe PDF
338.43 kB Adobe PDF Visualizza/Apri
jamaoncology_bolte_2023_br_220031_1684353169.78411 (1).pdf

accesso aperto

Tipologia: Versione editoriale (Publisher’s layout)
Licenza: Creative commons
Dimensione 272.51 kB
Formato Adobe PDF
272.51 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11572/388850
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 14
social impact